Heart and Seoul as IONTAS earns Korea antibody collaboration
IONTAS, a Cambridge-based specialist in the discovery and optimisation of fully human antibodies, has signed a collaboration agreement with Korean-based LG Chem for the discovery of therapeutic antibodies targeting undisclosed targets for use in the treatment of cancers.
The alliance will see IONTAS use its proprietary antibody discovery platforms to deliver antibodies against biological targets selected by LG Chem and further prove the biological activity of the antibodies.
Dr Neil Butt, CBO of IONTAS, said: “This new agreement marks IONTAS’ expansion into the Asian market and we are delighted to have been selected by LG Chem after a rigorous diligence process.
“The application of our proprietary technologies will assist LG Chem in expanding its current therapeutic pipeline by generating leads against pre-defined specifications agreed at the project outset.”
Dr Myung Jin Kim, executive VP/R & D leader, Life Sciences R & D of LG Chem added: “IONTAS was selected because of its robust track record and technical know-how. We feel confident this collaboration will result in a strong panel of therapeutic leads which will help develop our oncology pipeline.”
Dr Butt and Dr Mike Dyson have been evangelising the business at the BIO International Convention in Boston this week while CEO Dr John McCafferty has been at Antibody Engineering and Therapeutics Europe in Amsterdam.
As Business Weekly previously reported, IONTAS was recently awarded £556k from Innovative UK to develop therapies for chronic pain management.
As Cambridge continues to enhance its reputation in antibody development watch out for a fresh spurt of global investment in cluster companies here.